Beata Bode‐Lesniewska

University of Zurich

Papers

1

Total Citations

28

H-Index

1

About

Dr. Beata Bode-Lesniewska is a leading pathologist whose research focuses on the molecular characterization of rare soft tissue and bone tumors, with a particular emphasis on sarcomas and inflammatory myofibroblastic tumors (IMTs). Her major contributions lie in elucidating the genetic drivers of these neoplasms, especially ALK gene rearrangements, and translating these findings into targeted therapeutic strategies. Her highly cited 2020 study on an IMT of the bladder with a rare FN1-ALK gene fusion demonstrated a differential response to ALK inhibition, showing that while crizotinib failed to induce regression, it highlights the critical need for genotype-matched therapies in rare, unresectable tumors. This work, with 28 citations, underscores her impact on precision oncology for orphan diseases. Dr. Bode-Lesniewska’s expertise in integrating histopathology with molecular diagnostics has advanced the understanding of tumor biology and guided clinical decision-making, making her a pivotal figure in sarcoma research and a valuable resource for clinicians and scientists tackling diagnostically challenging malignancies.

Research Focus

Key Achievements

1
H-Index
1
Papers
28
Total Citations
28
Avg Citations/Paper
🏆 Most Cited Paper
Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition
28 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: University of Zurich

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago